Effect of NCOR1 Mutations on Immune Microenvironment and Efficacy of Immune Checkpoint Inhibitors in Patient with Bladder Cancer

Immune checkpoint blockade (ICB) therapy has significantly progressed the treatment of bladder cancer (BLCA). Multiple studies have suggested that specific genetic mutations may serve as immune biomarkers for ICB therapy. Additionally, the nuclear receptor corepressor 1 (NCOR1) gene is a new player...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Anqi, Qiu, Zhengang, Zhang, Jian, Luo, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982737/
https://www.ncbi.nlm.nih.gov/pubmed/33763074
http://dx.doi.org/10.3389/fimmu.2021.630773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7982737/
https://www.ncbi.nlm.nih.gov/pubmed/33763074
http://dx.doi.org/10.3389/fimmu.2021.630773

Ejemplares similares